Allstocks.com's Bulletin Board Post New Topic  New Poll  Post A Reply
my profile login | register | search | faq | forum home

  next oldest topic   next newest topic
» Allstocks.com's Bulletin Board » Micro Penny Stocks, Penny Stocks $0.10 & Under » GVBP HUGE NEWS (Page 2)

 - UBBFriend: Email this page to someone!   This topic comprises 2 pages: 1  2   
Author Topic: GVBP HUGE NEWS
Burberry Boy
Member


Member Rated:
4
Icon 1 posted      Profile for Burberry Boy     Send New Private Message       Edit/Delete Post   Reply With Quote 
sweet .67!

awesome news!

might see $1 again!

Posts: 1264 | Registered: Jul 2009  |  IP: Logged | Report this post to a Moderator
THE DUKE
Member


Rate Member
Icon 1 posted      Profile for THE DUKE         Edit/Delete Post   Reply With Quote 
There was a big communication problem this morning
otc communication for this stock was down. Back up and running now however knock out alot of stop-losses

Posts: 251 | From: nashville | Registered: Jan 2007  |  IP: Logged | Report this post to a Moderator
THE DUKE
Member


Rate Member
Icon 10 posted      Profile for THE DUKE         Edit/Delete Post   Reply With Quote 
Going up big-time.
Posts: 251 | From: nashville | Registered: Jan 2007  |  IP: Logged | Report this post to a Moderator
Hot-Pepper
Member


Member Rated:
4
Icon 1 posted      Profile for Hot-Pepper     Send New Private Message       Edit/Delete Post   Reply With Quote 
I sold around the drop. I got back in again at 0.44 with almost double the shares I previously bought. Thanks to the dip. Hopefully it stays up and continue to trade upwards, even though it's currently trading in the red. The green territory is achievable today. imo.
Posts: 602 | From: Minneapolis | Registered: Jul 2009  |  IP: Logged | Report this post to a Moderator
Hot-Pepper
Member


Member Rated:
4
Icon 1 posted      Profile for Hot-Pepper     Send New Private Message       Edit/Delete Post   Reply With Quote 
GENova Biotherapeutics secures new cancer drugs targets

Sep 17, 2009 06:00:00 (ET)


NEW YORK, Sept 17, 2009 /PRNewswire-FirstCall via COMTEX/ -- (OTCBB: GVBP.OB) - GENova Biotherapeutics Inc. ("GENova"), a biotechnology company that develops novel therapeutic proteins that disrupt the advance of life-threatening cancers, today announced it has signed a collaboration deal with Beckpharma Ltd. ("Beckpharma") -a pharmaceutical development company also involved in cancer treatments.

The two companies are joining forces in their mutual mission to identify, acquire, and out-license promising cancer drugs in an effort that will not only save millions on GENova's R D budget, but at the same time will significant increase GENova's distribution, the deal with Beckpharma is the latest deal in a string of deals that GENova has recently done in a continued effort to increase its IP portfolio and increase its distribution network.

"By combining our efforts with Beckpharma's, we are casting a wider net when it comes to sourcing new cancer drug targets. Beckpharma has close relationships with academic research institutions around the world, and now, through this collaboration, their industry contacts become ours, and vice versa," says Aaron Whiteman, CEO for GENova.

This collaboration will bolster GENova's acquisition activities and funnel more promising drug targets into its drug development pipeline. GENova will also leverage the scientific expertise of Beckpharma's Research and Development Team, as well as its established distribution channels with Big Pharmaceutical companies.

Furthermore, scientists in both GENova and Beckpharma are examining their current IP portfolios to gain insight into possible synergies between their drug targets, and the possibility of making a stronger, better, combined product by coordinating their biotechnologies.

"This is a positive step for GENova," says Whiteman. "Through our collaboration with Beckpharma we are gaining access to their technologies and relationships, and we hope to leverage that to bring our patents to market faster, and thus start reaping payments on our potential blockbuster drug patents".

About Beckpharma

Beckpharma is a pharmaceutical development company whose mission is to take marketed products, as well as products at all stages of clinical development, from targeted academic institutes and other sources, add value to those products, and then commercialise them through its own resources or through industry partners in Europe, North America and other suitable territories.

Posts: 602 | From: Minneapolis | Registered: Jul 2009  |  IP: Logged | Report this post to a Moderator
Hot-Pepper
Member


Member Rated:
4
Icon 1 posted      Profile for Hot-Pepper     Send New Private Message       Edit/Delete Post   Reply With Quote 
GENova Biotherapeutics signs LOI with Korean university for stem cell research and patents sharingFont size: A | A | A7:04 PM ET 9/17/09 | PR Newswire
(OTCBB: GVBP.OB) - GENova Biotherapeutics Inc. ("GENova") today announced that it has signed a LOI for a strategic partnership agreement with the Hospital Medical Information Department of Suncheon Cheongam University in Seoul, South Korea to gain access to its ground-breaking cancer stem cell research information.

University Department Head Sung-hong Kim recently formalized his intent to collaborate with GENova in an official Letter of Intent for Cooperation last month. The two organizations are negotiating the final terms and conditions of a partnership arrangement that would give GENova access to the university's exclusive IP information on cancer stem cell research in exchange for yet to be disclosed amount into the University's research projects.

This partnership with Suncheon Cheongam will be the latest addition to GENova's estimable list of global strategic alliances which include arrangements with universities, research labs, hospitals, biotechnology companies, and contract research organizations around the globe. This latest partnership will represent's GENova's first relationship with a Korean-based organization and become the spring board for GENova to seek further collaborations agreements with Asian medical Universities.

The timing of this pending partnership with a Korean university is particularly opportune in light of a recent proposal that could place Korea among the top five countries in stem cell research by 2015. In August 2009 Korea's government announced its intent to boost its investment in stem cell research by US$33 million a year, reaching $98 million by 2015. Korea's current total investment in the biotechnology sector amounts to $980 million. This increase in funding will only serve to stimulate the quality already high quality of stem cell research coming out of Korea.

About GENova Biotherapeutics Inc.

GENova is positioning itself as the world's leading bioscience company in the development and commercial licensing of novel therapeutic proteins that disrupt the advance of life-threatening cancers. The company leverages cutting-edge research collaborations to achieve breakthroughs in anti-cancer treatments, and then licenses these drug product candidates to Big Pharmaceutical and Biotechnology companies such as Pfizer, Amgen, Myriad Genetics, Medarex, and Biogen Idec. Visit GENova online at: www.genovabio.com.

Forward Looking Statements

This document includes certain statements that may be deemed to be "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, are expected by the Company to be forward-looking statements. Although GENova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include but are not limited to the success of the owned intellectual property, the strength of the patents, continued availability of capital and financing, and general economic market or business conditions.

SOURCE GENova Biotherapeutics, Inc.

Posts: 602 | From: Minneapolis | Registered: Jul 2009  |  IP: Logged | Report this post to a Moderator
  This topic comprises 2 pages: 1  2   

Quick Reply
Message:

HTML is not enabled.
UBB Code™ is enabled.

Instant Graemlins
   


Post New Topic  New Poll  Post A Reply Close Topic   Feature Topic   Move Topic   Delete Topic next oldest topic   next newest topic
 - Printer-friendly view of this topic
Hop To:


Contact Us | Allstocks.com Message Board Home

© 1997 - 2019 Allstocks.com. All rights reserved.

Powered by Infopop Corporation
UBB.classic™ 6.7.2

Share